These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 1698251)

  • 1. Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors.
    Rodriguez M; Lignon MF; Galas MC; Amblard M; Martinez J
    Mol Pharmacol; 1990 Sep; 38(3):333-41. PubMed ID: 1698251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702.
    Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP
    Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.
    Zhou W; Povoski SP; Bell RH
    J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
    Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of cyclic analogues of cholecystokinin highly selective for central receptors.
    Rodriguez M; Amblard M; Galas MC; Lignon MF; Aumelas A; Martinez J
    Int J Pept Protein Res; 1990 May; 35(5):441-51. PubMed ID: 2376470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship studies on cholecystokinin: analogues with partial agonist activity.
    Galas MC; Lignon MF; Rodriguez M; Mendre C; Fulcrand P; Laur J; Martinez J
    Am J Physiol; 1988 Feb; 254(2 Pt 1):G176-82. PubMed ID: 2450468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.
    Knapp RJ; Vaughn LK; Fang SN; Bogert CL; Yamamura MS; Hruby VJ; Yamamura HI
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1278-86. PubMed ID: 2262906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel CCK analogues and bombesin: a detailed analysis between phosphoinositide breakdown and high-dose inhibition of pancreatic enzyme secretion in three rodent species.
    Bianchi BR; Miller TR; Witte DG; Lin CW
    J Pharmacol Exp Ther; 1994 Feb; 268(2):996-1002. PubMed ID: 7509394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
    Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
    J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological activity of cholecystokinin analogues modified in the Met28-Gly29 region.
    Mendre C; Rodriguez M; Lignon MF; Galas MC; Gueudet C; Worms P; Martinez J
    Eur J Pharmacol; 1990 Sep; 186(2-3):213-22. PubMed ID: 1705230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of some partially modified retro-inverso analogues of cholecystokinin.
    Rodriguez M; Galas MC; Lignon MF; Mendre C; Laur J; Aumelas A; Martinez J
    J Med Chem; 1989 Oct; 32(10):2331-9. PubMed ID: 2477546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds.
    Rodriguez M; Lignon MF; Galas MC; Fulcrand P; Mendre C; Aumelas A; Laur J; Martinez J
    J Med Chem; 1987 Aug; 30(8):1366-73. PubMed ID: 2441054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin receptors: relationships among phosphoinositide breakdown, amylase release and receptor affinity in pancreas.
    Lin CW; Bianchi BR; Grant D; Miller T; Danaher EA; Tufano MD; Kopecka H; Nadzan AM
    J Pharmacol Exp Ther; 1986 Mar; 236(3):729-34. PubMed ID: 2419543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pseudopeptide that is a potent cholecystokinin agonist in the peripheral system is able to inhibit the dopamine-like effects of cholecystokinin in the striatum.
    Mendre C; Rodriquez M; Gueudet C; Lignon MF; Galas MC; Laur J; Worms P; Martinez J
    J Biol Chem; 1988 Aug; 263(22):10641-5. PubMed ID: 3392031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
    Poirot SS; Escrieut C; Dufresne M; Martinez J; Bouisson M; Vaysse N; Fourmy D
    Mol Pharmacol; 1994 Apr; 45(4):599-607. PubMed ID: 8183238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic cholecystokinin analogues with high selectivity for central receptors.
    Charpentier B; Pelaprat D; Durieux C; Dor A; Reibaud M; Blanchard JC; Roques BP
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1968-72. PubMed ID: 3162318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.